BRPI0818736A2 - composições e métodos para intensificar imunorrepostas à bactéria flagelada - Google Patents

composições e métodos para intensificar imunorrepostas à bactéria flagelada

Info

Publication number
BRPI0818736A2
BRPI0818736A2 BRPI0818736A BRPI0818736A BRPI0818736A2 BR PI0818736 A2 BRPI0818736 A2 BR PI0818736A2 BR PI0818736 A BRPI0818736 A BR PI0818736A BR PI0818736 A BRPI0818736 A BR PI0818736A BR PI0818736 A2 BRPI0818736 A2 BR PI0818736A2
Authority
BR
Brazil
Prior art keywords
immunoresponders
enhancing
compositions
methods
flagellated bacteria
Prior art date
Application number
BRPI0818736A
Other languages
English (en)
Portuguese (pt)
Inventor
Hargis Billy
Cole Kimberly
Berghman Luc
Cox Mandy
Layton Sherryll
Bottje Walter
Min Kwon Young
Original Assignee
Univ Arkansas
The Texas A&M Univeristy System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arkansas, The Texas A&M Univeristy System filed Critical Univ Arkansas
Publication of BRPI0818736A2 publication Critical patent/BRPI0818736A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI0818736A 2007-10-30 2008-10-30 composições e métodos para intensificar imunorrepostas à bactéria flagelada BRPI0818736A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98380307P 2007-10-30 2007-10-30
PCT/US2008/081813 WO2009059018A1 (en) 2007-10-30 2008-10-30 Compositions and methods of enhancing immune responses to flagellated bacterium

Publications (1)

Publication Number Publication Date
BRPI0818736A2 true BRPI0818736A2 (pt) 2017-06-13

Family

ID=40591464

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0818736A BRPI0818736A2 (pt) 2007-10-30 2008-10-30 composições e métodos para intensificar imunorrepostas à bactéria flagelada

Country Status (9)

Country Link
US (1) US9125854B2 (OSRAM)
EP (1) EP2214840B1 (OSRAM)
JP (1) JP2011502165A (OSRAM)
CN (1) CN102037135A (OSRAM)
AU (1) AU2008318615A1 (OSRAM)
BR (1) BRPI0818736A2 (OSRAM)
CA (1) CA2704457A1 (OSRAM)
NZ (1) NZ585776A (OSRAM)
WO (1) WO2009059018A1 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2520026T3 (es) * 2006-09-18 2014-11-11 The Board Of Trustees Of The University Of Arkansas Composiciones y métodos para potenciar respuestas inmunitarias
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
CA3051748C (en) 2007-11-01 2022-07-12 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to eimeria
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
PL2525817T3 (pl) 2010-01-21 2018-01-31 Univ Arkansas Wektory szczepionkowe i sposoby wzmacniania odpowiedzi immunologicznych
EA030793B1 (ru) 2010-06-09 2018-09-28 Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Арканзас Рекомбинантный вакцинный вектор против инфекции campylobacter и способы усиления иммунного ответа на campylobacter и повышения устойчивости к инфекции campylobacter
CA2895805A1 (en) 2012-12-18 2014-06-26 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
JP6532407B2 (ja) 2013-02-14 2019-06-19 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー アイメリアに対する免疫応答を強化するか又はアイメリア感染症を制限する組成物及び方法
CN105142653B (zh) 2013-03-15 2019-11-15 阿肯色大学评议会 增强对肠病原体免疫应答的组合物和方法
CN104789583A (zh) * 2014-01-20 2015-07-22 华中农业大学 一种人源产肠毒素大肠杆菌鞭毛蛋白2FliC融合蛋白及其应用
CN104328136B (zh) * 2014-10-03 2018-04-17 哈尔滨博翱生物医药技术开发有限公司 鸡新城疫病毒毒株rClone30‑fliC的制备及其在鸡新城疫病防治中的应用
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
SG11201809686SA (en) 2016-05-03 2018-11-29 Univ Arkansas Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
WO2019040135A1 (en) * 2017-05-12 2019-02-28 Children's Medical Center Corporation NUCLEIC ACIDS HANDLING IMMUNEWAYS

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4420497A (en) * 1981-08-24 1983-12-13 Fairchild Camera And Instrument Corporation Method of detecting and repairing latent defects in a semiconductor dielectric layer
US4510674A (en) * 1982-10-21 1985-04-16 Sovonics Solar Systems System for eliminating short circuit current paths in photovoltaic devices
CA2099841C (en) 1991-03-05 2003-02-25 Ian G. Charles Expression of recombinant proteins in attenuated bacteria
WO1993008207A1 (en) 1991-10-25 1993-04-29 Immunex Corporation Novel cytokine
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US5981724A (en) 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
DE69322092T2 (de) 1992-09-04 1999-07-15 University Of Saskatchewan, Saskatoon Neue bakterielle impfstoffe unter verwendung von impfstämmen von pathogenen bakterien
AU1059095A (en) 1993-11-24 1995-06-13 Australian National University, The Treatment of viral disease with cd40l peptide
JP3657271B2 (ja) 1995-03-01 2005-06-08 イミュネックス・コーポレーション 病原性または日和見感染性生物に感染した哺乳動物の治療のための組成物
IL122174A (en) 1995-06-07 2004-07-25 Immunex Corp Dna encoding a cd40l mutein and a cd40l polypeptide encoded by said dna
US5800632A (en) * 1995-09-28 1998-09-01 Canon Kabushiki Kaisha Photovoltaic device and method for manufacturing it
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US6306387B1 (en) 1997-05-29 2001-10-23 The Research Foundation Of State University Of New York Antigen delivery system
US6969609B1 (en) 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
CA2223225A1 (en) 1997-11-28 1999-05-28 Canadian Red Cross Society Method for inhibiting in vivo immune response
IL136731A0 (en) 1997-12-19 2001-06-14 Immunex Corp Method for reducing susceptibility to hiv infection
GB9806449D0 (en) 1998-03-25 1998-05-27 Peptide Therapeutics Ltd Attenuated bacteria useful in vaccines
US6190669B1 (en) 1998-05-13 2001-02-20 University Of Maryland, Baltimore Attenuated mutants of salmonella which constitutively express the Vi antigen
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
ATE486940T1 (de) 1998-09-04 2010-11-15 Emergent Product Dev Uk Ltd Abgeschwächte salmonella sp12 mutante als antigen-träger.
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
EP1067194A1 (en) 1999-04-16 2001-01-10 F. Hoffmann-La Roche Ag Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
WO2000063395A1 (en) 1999-04-16 2000-10-26 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
WO2001026608A2 (en) * 1999-10-14 2001-04-19 Ledbetter Jeffrey A Dna vaccines encoding antigen linked to a domain that binds cd40
DK1112747T3 (da) 1999-12-28 2004-10-25 Akzo Nobel Nv Salmonellavaccine, som ikke inducerer antistoffer mod flagellin eller flageller
WO2001056602A2 (en) 2000-02-02 2001-08-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cd40 ligand adjuvant for respiratory syncytial virus
ES2244617T3 (es) 2000-03-17 2005-12-16 Pharmacia & Upjohn Co Llc Vacunas a base de salmonelas en las cuales los genes ssa han sido inactivados.
GB0015426D0 (en) 2000-06-24 2000-08-16 Univ Southampton Method for generating soluble highly multimeric proteins
AU2002221780A1 (en) 2000-10-31 2002-05-15 F.Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
US8703146B2 (en) 2001-04-20 2014-04-22 Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
EP2107110A3 (en) 2001-05-15 2011-10-26 Ortho-McNeil Pharmaceutical, Inc. Ex-vivo priming for generating cytotoxic T lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease
US6923958B2 (en) 2002-03-02 2005-08-02 The Scripps Research Institute DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
WO2003096812A1 (en) * 2002-04-15 2003-11-27 Washington University Regulated attenuation of live vaccines to enhance cross protective immunogenicity
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
US20050181994A1 (en) 2003-01-06 2005-08-18 Xencor, Inc. Novel variants of CD40L protein
US20060014248A1 (en) 2003-01-06 2006-01-19 Xencor, Inc. TNF super family members with altered immunogenicity
US7754209B2 (en) * 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
WO2005035570A2 (en) 2003-10-10 2005-04-21 Xencor, Inc. Variants of cd40l protein
EP1720905A2 (en) 2003-12-11 2006-11-15 Sidney Kimmel Cancer Center Methods for generating immunity to antigen
US8828957B2 (en) 2003-12-11 2014-09-09 Microvax, Llc Methods for generating immunity to antigen
US7098058B1 (en) * 2004-01-15 2006-08-29 University Of Toledo Photovoltaic healing of non-uniformities in semiconductor devices
EP1740604A2 (en) 2004-04-27 2007-01-10 Intercell AG Td antigens
WO2005113598A2 (en) 2004-05-21 2005-12-01 Xencor, Inc. Tnf super family members with altered immunogenicity
WO2006034268A2 (en) * 2004-09-20 2006-03-30 Georgia Tech Research Corporation Photovoltaic cell
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
WO2006042177A2 (en) 2004-10-07 2006-04-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
WO2006105972A1 (en) 2005-04-07 2006-10-12 Universite Libre De Bruxelles Transgenic organism expressing cd40l and uses thereof
US20060286074A1 (en) 2005-05-31 2006-12-21 Yucheng Tang Methods for immunotherapy of cancer
RU2431499C2 (ru) 2005-10-07 2011-10-20 Пройекто Де Биомедисина Сима, С.Л. Иммуностимулирующая комбинация для профилактики и лечения гепатита с
WO2007056266A2 (en) 2005-11-07 2007-05-18 Sidney Kimmel Cancer Center Cd40 ligand fusion protein vaccine
WO2007054658A1 (en) 2005-11-14 2007-05-18 King's College London Control of immune responses
WO2007103048A2 (en) * 2006-03-01 2007-09-13 Regents Of The University Of Colorado Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
US8802419B2 (en) 2006-03-02 2014-08-12 University Of Massachusetts Modified pathogens for use as vaccines
US20070227586A1 (en) * 2006-03-31 2007-10-04 Kla-Tencor Technologies Corporation Detection and ablation of localized shunting defects in photovoltaics
ES2520026T3 (es) 2006-09-18 2014-11-11 The Board Of Trustees Of The University Of Arkansas Composiciones y métodos para potenciar respuestas inmunitarias
WO2008109825A2 (en) 2007-03-08 2008-09-12 Mayo Foundation For Medical Education And Research Inducing immune-mediated tumor cell death
CA3051748C (en) 2007-11-01 2022-07-12 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to eimeria

Also Published As

Publication number Publication date
HK1146644A1 (en) 2011-06-24
AU2008318615A1 (en) 2009-05-07
AU2008318615A2 (en) 2010-06-24
WO2009059018A9 (en) 2009-12-30
US9125854B2 (en) 2015-09-08
JP2011502165A (ja) 2011-01-20
WO2009059018A1 (en) 2009-05-07
US20110159026A1 (en) 2011-06-30
EP2214840A4 (en) 2012-03-07
EP2214840A1 (en) 2010-08-11
CN102037135A (zh) 2011-04-27
CA2704457A1 (en) 2009-05-07
NZ585776A (en) 2012-07-27
EP2214840B1 (en) 2015-05-06

Similar Documents

Publication Publication Date Title
BRPI0818736A2 (pt) composições e métodos para intensificar imunorrepostas à bactéria flagelada
PT2144998T (pt) Métodos e composições para vírus vivos atenuados
BRPI0815407A2 (pt) Composições e métodos para controlar nematódeos
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
LT2596784T (lt) Tapentadolio kompozicijos
BRPI0914713A2 (pt) composição para cuidado oral
PT2868315T (pt) Formulações melhoradas e métodos para liofilização e liofilizados assim produzidos
BRPI0814594A2 (pt) Composições e métodos adjuvantes de antígeno
BRPI0812562A2 (pt) composições terapêuticas anti-cd20 e métodos
PT2448582T (pt) Compostos e composições terapêuticas
BRPI0813647A2 (pt) Piperazinil oxoalquil tetrahidro-beta-carbolinas e análogos relacionados
BRPI0810634A2 (pt) Composições fungicidas
BRPI0810929A2 (pt) "método para proteger"
BRPI0820980A2 (pt) Composições e métodos para detecção de tiabs
BRPI0813775A2 (pt) Composição
DK3492069T3 (da) Farmaceutiske sammensætninger omfattende jern-oxy-hydroxid
ATE528048T1 (de) Schweisshemmende/desodorierende zusammensetzung
FI20096058A0 (fi) Koostumuksia ja niihin liittyviä menetelmiä ja käyttöjä
BRPI0814188A2 (pt) Formulações
ATE526567T1 (de) Zusammensteller und zusammenstellungsverfahren
BRPI0811274A2 (pt) Composição
BRPI0810557A2 (pt) composição
EP2197828A4 (en) FULLERENE MULTI-ADDUCT COMPOSITIONS
BRPI0722183A2 (pt) Composições farmacêuticas para tratar depressão e ansiedade
BRPI0811002A2 (pt) Composição biofertilizante

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]